Japan Becomes First Country to Approve Reprogrammed Cell Treatments for Human Use
Tokyo, Saturday, 14 March 2026.
Japan’s health ministry has granted world-first regulatory approval for two medical treatments using reprogrammed human cells, marking a revolutionary milestone in regenerative medicine. The approved therapies include ReHeart for severe heart failure and Amusepri for Parkinson’s disease, both derived from induced pluripotent stem cells that can transform into any cell type. This breakthrough comes exactly twenty years after Japanese researcher Shinya Yamanaka pioneered the technology that won him a Nobel Prize, positioning Japan as the global leader in commercializing cellular reprogramming for medical applications.
Revolutionary Medical Innovation Classification and Benefits
This development represents a breakthrough in healthtech and regenerative medicine, specifically targeting severe medical conditions through cellular reprogramming technology. On March 6, 2026, Japan’s Ministry of Health, Labor and Welfare granted conditional and time-limited marketing authorization to two regenerative medical products derived from reprogrammed induced pluripotent stem (iPS) cells [1]. These authorizations mark the world’s first practical application of iPS cell-derived products for commercial medical use [1]. The technology offers transformative benefits by addressing underlying cellular degeneration rather than merely managing symptoms, as traditional pharmaceuticals do [2]. iPS cells are adult cells reprogrammed to function like embryonic stem cells, capable of dividing indefinitely and taking the form of any cell type in the human body [1].
ReHeart: Revolutionary Treatment for Heart Failure
The first approved product, ReHeart, comes from Qualipse, a startup based at Osaka University [1]. ReHeart consists of a sheet of cardiomyocytes differentiated from iPS cells of healthy donors, specifically intended for patients with severe heart failure due to ischemic cardiomyopathy [1]. The treatment process involves attaching three sheets of cardiomyocytes to the surface of the heart via surgery in the left side of the chest [1]. In a clinical study of eight patients, four showed improvement, with peak oxygen consumption increasing by more than 10 percent at 52 weeks post-transplant [1]. A comprehensive study of ReHeart’s use outcomes in a target number of 75 patients is planned, with sales expected to start around the fall of 2026 [1].
Amusepri: Breakthrough Parkinson’s Disease Therapy
The second approved treatment, Amusepri (laguneprocell), represents a collaboration between Sumitomo Pharma and Racthera [1]. Amusepri consists of precursor cells destined to become dopamine-producing neurons, indicated for improving motor symptoms in Parkinson’s disease patients [1]. A trial at Kyoto University Hospital demonstrated promising results, with four of six patients showing improvement in their off-time score 24 months after transplantation [1]. The production of Amusepri takes place at SMaRT in Suita City, Osaka Prefecture, which serves as the world’s first commercial manufacturing facility dedicated to regenerative medicine and cell-based drugs derived from donor iPS cells [1]. Like ReHeart, Amusepri is also required to gather additional data for official approval [1].
The Scientific Pioneer Behind the Technology
The breakthrough builds upon two decades of research pioneered by Dr. Shinya Yamanaka, director emeritus of the iPS Cell Research Institute at Kyoto University, who won the Nobel Prize in Physiology or Medicine in 2012 for the discovery of induced pluripotent stem cells [1][2]. Yamanaka expressed satisfaction with this milestone, stating: ‘We are very pleased to have taken a major step toward social application on the 20th anniversary of the announcement of mouse iPS cells. I believe it is important that we continue to move forward steadily, step by step, with scientific caution and without getting carried away’ [1]. Jun Takahashi, current director of the iPS Cell Research Institute at Kyoto University, emphasized that ‘the results of the deliberations are a major step forward, but even if approval is granted, that is not the goal, but only the beginning of this new medicine’ [1]. Health Minister Kenichiro Ueno highlighted the global significance, noting his pleasure ‘that a therapeutic product from Japan based on professor Yamanaka’s iPS cells has been put into practice for the first time in the world, and I hope it will help patients not only in Japan but all over the world’ [1].